Breast cancers can also be characterized by gene mutation status such as germline BRCA1/2 and somatic PIK3CA mutations [7–9], which can indicate eligibility for targeted inhibitors to PARP or PIK3CA, respectively, or by progressive mutation in the gene for ER (ESR1) which indicates loss of sensitivity to some endocrine therapies [10]. This evidence concerns the gene ESR1 and breast carcinoma.